Primary source: View
Continuous monitoring of adverse reactions related to the use of Rezolsta is now a regulatory requirement.
This action ensures that any potential safety issues with Rezolsta are identified and addressed promptly, maintaining patient safety.
The pharmacovigilance department must increase reporting obligations for any adverse effects related to Rezolsta as part of ongoing safety monitoring.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
The pharmacovigilance department must increase reporting obligations for any adverse effects related to Rezolsta as part of ongoing safety monitoring.
The European Medicines Agency (EMA) has confirmed the authorization of Rezolsta, a combination of darunavir and cobicistat, for use in the European Union. The medicine is intended for adults and children over 6 years old weighing at least 25 kg to treat HIV-1, used alongside other antiretroviral therapies. Post-authorization surveillance will continuously monitor usage data and adverse reactions.
What changed: Continuous monitoring of adverse reactions related to the use of Rezolsta is now a regulatory requirement.
Why it matters: This action ensures that any potential safety issues with Rezolsta are identified and addressed promptly, maintaining patient safety.
Practical implication: The pharmacovigilance department must increase reporting obligations for any adverse effects related to Rezolsta as part of ongoing safety monitoring.
Published from the regulator source ingestion pipeline after PV impact triage.
Healthcare professionals must administer Kavigale in a monitored clinical environment to manage potential severe allergic reactions, including anaphylaxis.
Implement resource allocation for increased monitoring of reported adverse reactions specific to Vislyfa as per the new safety evaluation requirements.
Stakeholders must review and update the labeling of Benlysta in accordance with the new indications highlighted in the EPAR.
Update labeling and handle regulatory documentation to reflect the new approved indication for sevabertinib, including dosage guidance of 20 mg orally twice daily.
